Drugs / LMB-9
LMB-9
also known as
B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38
Protein / enzyme biologic targets EEF2 via inhibition
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00010270 | Apr 2001 → ? | colorectal cancer, esophageal cancer, gastric cancer, malignant pancreatic neoplasm | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 1 | NCT00019435 | May 1998 → ? | breast cancer, colorectal cancer, esophageal cancer, gastric cancer +3 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMB-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00010270 ↗ |
| Known as | B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109503 ↗ |
| Action | Deplete | “LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.” NCT00010270 ↗ |
| Action | Inhibit | “Elongation factor 2 inhibitor” CHEMBL2109503 ↗ |
| Modality | Protein / enzyme biologic | “LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin” NCT00010270 ↗ |
| Route | Intravenous | “Patients receive LMB-9 immunotoxin IV continuously on days 1-5.” NCT00010270 ↗ |
| Target | EEF2 | “Elongation factor 2 inhibitor” CHEMBL2109503 ↗ |